Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 46, Issue 11 (Nov 2008)

Issues

Natriuretic peptide testing in emergency settings

Jordi Ordonez-Llanos
  • 1Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma, Barcelona, Spain
/ Javier Merce-Muntanola
  • 2Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
/ Miquel Santalo-Bel
  • 3Unitat de Semicrítics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Abstract

Acutely dyspneic patients are challenging, because their symptoms can be due to cardiac, pulmonary or other diseases. B-type natriuretic peptide testing offers higher diagnostic accuracy (85%–90%) than clinical assessments for identifying heart failure as the cause of dyspnea. On the other hand, the high clinical sensitivity and negative predictive value of natriuretic peptides permit to rule out heart failure with an accuracy >90%. Natriuretic peptides are the most powerful, single prognostic markers of complications associated with acute dyspnea and permit the early recognition of high-risk patients. It has been shown that systematic natriuretic peptide testing reduces the economic expenses associated with clinical management of acutely dyspneic patients. Finally, whether these biomarkers could be used to guide heart failure therapy in the acute setting remains to be elucidated.

Clin Chem Lab Med 2008;46:1543–9.

Keywords: acute heart failure; B-type natriuretic peptides; cost-benefit; diagnostic gray zone; prognosis

About the article

Corresponding author: Jordi Ordonez-Llanos, MD, PhD, Servei de Bioquímica, Hospital de la Santa Creu i Sant Pau, Avinguda Sant Antoni Maria Claret 167, 08025 Barcelona, Spain Phone: +34-93-2919451, Fax: +34-93-2919196,


Received: 2008-07-12

Accepted: 2008-09-12

Published in Print: 2008-11-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2008.298. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Colleen Austel Nadeau, Ana-Maria Gallo, and Willa Fields
Journal of Nursing Care Quality, 2014, Volume 29, Number 1, Page 38
[2]
David R. McIlroy, Sophie Wallace, and Nicholas Roubos
Journal of Cardiothoracic and Vascular Anesthesia, 2010, Volume 24, Number 6, Page 939
[3]
Mario Plebani and Karl Lackner
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 5

Comments (0)

Please log in or register to comment.
Log in